Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen

TD Cowen initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report report published on Friday morning, Marketbeat reports. The firm issued a buy rating on the stock.

A number of other research firms also recently commented on DNTH. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Oppenheimer raised their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Finally, Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $23.80 on Friday. The company’s fifty day moving average price is $25.77 and its two-hundred day moving average price is $26.60. The firm has a market capitalization of $704.41 million, a P/E ratio of -9.52 and a beta of 1.74. Dianthus Therapeutics has a 12 month low of $7.75 and a 12 month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. On average, sell-side analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Quest Partners LLC raised its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth $112,000. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter worth $236,000. Fred Alger Management LLC boosted its stake in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after buying an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics during the second quarter worth about $265,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.